Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 585.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 213,431 shares of the company's stock after purchasing an additional 182,314 shares during the period. JPMorgan Chase & Co. owned approximately 0.53% of Keros Therapeutics worth $3,379,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Barclays PLC increased its stake in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after buying an additional 35,022 shares during the period. Geode Capital Management LLC raised its holdings in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after purchasing an additional 46,041 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the fourth quarter valued at about $388,000. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics in the fourth quarter valued at about $99,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after purchasing an additional 1,372 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KROS has been the subject of several recent analyst reports. Scotiabank reduced their price target on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Oppenheimer decreased their price target on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Keros Therapeutics Trading Down 1.1 %

Shares of Keros Therapeutics stock traded down $0.17 during mid-day trading on Friday, hitting $14.26. 450,885 shares of the stock were exchanged, compared to its average volume of 794,996. The company has a 50-day simple moving average of $11.49 and a 200 day simple moving average of $28.18. The stock has a market capitalization of $578.21 million, a price-to-earnings ratio of -2.74 and a beta of 1.39. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 22.90% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.